Document is current

Article History

Received: 6 March 2025

Accepted: 20 March 2025

First Online: 3 April 2025

Declarations

:

: Not applicable.

: RM– consultant (honoraria) over 3 years: Abbvie, Blueprint, BMS, CTI, Genentech, Geron, GSK, Incyte, Novartis, Sierra, Sierra Oncology, Telios; research support: Abbvie, Blueprint, BMS, CTI, Genentech, Incyte, Morphosys, Sierra. AY– advisory board for AbbVie, Acceleron Pharma Inc., Apellis Pharmaceuticals, Celgene, CTI BioPharma, Gilead Sciences, Incyte Corporation, Notable Labs, Inc., Novartis, PharmaEssentia, Pfizer, and Servier. TT– advisory board for Blueprint Medicines, Cogent Biosciences, PharmaEssentia; primary investigator in trials funded by Blueprint Medicines, Cogent Biosciences, Italfarmaco SpA, PharmaEssentia, Sanofi, Telios Pharma. WCH– advisory board: Ascentage Pharma. CHY– consulting fees from PharmaEssentia. JM– research funding paid to Tisch Cancer Institute (New York) from Abbvie, BMS, Novartis, Incyte, Kartos, Karyopharm, SOBI, DISC, AJAX, Geron, PharmaEssentia, Italfarmaco SpA and consulting fees from Abbvie, BMS, Novartis, Incyte, GSK, Geron, Kartos, Karyopharm, SOBI, Roche, Merck, MorphoSys, Pfizer, DISC, PharmaEssentia, Blueprint Medicines, Keros, and Sumitomo.